These 2 Discounted Stocks Rose Over 15% Last Week: Should You Buy?

Despite the recent uptrend, I am skeptical about these two stocks and would like to avoid them in the near term.

| More on:

Amid easing concerns over COVID-19 and rising commodity prices, the S&P/TSX Composite Index rose by 2.6% last week. However, the following two cheap Canadian stocks rose over 15%, outperforming the broader equity market. So, let’s assess whether the uptrend in these two stocks could continue, perhaps providing excellent buying opportunities.

Real Matters

Last month, Real Matters (TSX:REAL) reported its first-quarter earnings, with its top-line declining by 10.4%. The growth in the U.S. appraisal and Canadian segments was more than offset by a 59.4% decline in revenue from the U.S. title segment, dragging the company’s overall revenue down. Amid the decline in its revenue, its adjusted EBITDA and EPS also fell by 66% and 71.4%, respectively. The company’s management blamed the volatility in 10-year bond yields for creating headwinds for its business.

Amid the weak performances, Real Matters had witnessed a steep correction over the last 13 months, with its stock price falling over 70%. Meanwhile, investor appear to believe the sell-off is overdone, thus leading to a recovery in its stock price last week, with its stock price rising by 15.6%. Despite the surge, the company is still trading at a reasonable forward price-to-earnings multiple of 18.5. Also, analysts favour a ‘hold’ rating for the stock, with their consensus price target representing an upside potential of over 50%.

Meanwhile, with inflation at a multi-decade high, the U.S. Federal Reserve could increase interest rates multiple times this year. Higher interest rates could lower refinancing volumes, thus hurting the company’s financials. So, I would avoid this stock in the near term.

HEXO

Second on my list would be Hexo (TSX:HEXO), which rose 21.5% last week. Despite the surge, the company trades at a 95% discount from its 52-week high. In its recently reported first-quarter earnings, the company’s revenue increased by 29% on a sequential basis to $50.2 million, with the acquisition of Redecan and 48North contributing $14.6 million to its revenue. However, its net losses increased to $116.9 million, representing a sequential increase of 72%. The rising losses and weakness in the cannabis sector dragged the company’s stock price down.

Meanwhile, HEXO’s management has undertaken several cost-cutting initiatives, such as the closure of redundant production facilities, reduction of its selling, general, and administrative expenses, optimizing its production network, and leveraging the capabilities of its recent acquisitions. The company expects these initiatives to deliver incremental cash flows of $37.5 million in fiscal 2022 and $135 million in fiscal 2023. The company is also expanding its product offerings and geographically expanding its product availability to drive growth.

Amid the steep correction in its stock price, HEXO’s forward price-to-sales and price-to-book have fallen to 1.1 and 0.2, respectively. Meanwhile, among the eight analysts covering the stock, four have issued a ‘hold’ rating, while three have issued a ‘buy’ rating, and one analyst has issued a ‘sell’ rating. Analysts’ consensus price target represents an upside potential of over 280%.

Despite the company’s recent initiatives, I am skeptical of its financials improving in the near term. So, I would like to avoid HEXO in the near term and instead invest in Tilray, which has been reporting positive adjusted EBITDA for the previous 11 quarters.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends HEXO Corp. and Real Matters Inc. Fool contributor Rajiv Nanjapla has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Should You Buy Canopy Growth Stock or Green Thumb Stock Today?

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Could Aurora Cannabis Stock Finally Recover by Year-End?

Down 99% from all-time highs, Aurora Cannabis stock is focused on improving profit margins and expanding sales of its medical…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Are Pot Stocks About to Surge Again? 

With pot stocks making big moves of late, many investors are now asking whether the cannabis sector is worth investing…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »